Clinical TrialsSearch results
Number of results: 527
Other
- Phase I/II Study of Topotecan and Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
- Relapse/ refractory pediatric solid tumor
- Group for "making evidence for the drugs which are available in clinical practice in Europe and USA but not available in Japan"
- 2008-02-16
Recruiting
- Phase I/II study of KA-301 for acute spinal cord injury
- acute spinal cord injury
- Maeda Takeshi
- 2023-08-08
Other
- Phase I/II study of intermittent erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer
- Non-small cell lung cancer
- West Japan Oncology Group
- 2009-03-17
Other
- Phase I/II study of hepatic arterial infusion chemotherapy of gemcitabine for unresectable cholangiocarcinoma (JIVROSG-0301)
- Unresectable cholangiocarcinoma
- Japan Interventional Radiology in Oncology Study Group (JIVROSG)
- 2005-08-07
Other
- Phase I/II study of docetaxel, CDDP and 5-FU therapy in patients with unresectable or recurrent esophageal cancer (JCOG 0807)
- esophageal neoplasm
- Japan Clinical Oncology Group (JCOG)
- 2009-02-27
Other
- Phase I-II clinical trial of irinotecan hydrochloride (CPT-11) for refractory pediatric solid tumors
- Recurrent or progressive pediatric solid tumors (except for malignant lymphoma)
- CPT-PED-05 administrative office
- 2006-01-27
Other
- Phase I Study of gemtuzumab ozogamicin in combination with cytarabinne and idarubicin as induction therapy for relapsed or refractory patients with acute myeloid leukemia.
- Acute Myeloid Leukemia
- Japan Adult Leukemia Study Group
- 2008-05-10
Other
- Phase I study of Docetaxel, Cisplatin and S-1 in patients with advanced or recurrent gastric cancer
- Gastric cancer
- Shizuoka Cancer Center
- 2008-01-09
Other
- Phase 3 Study of SDT-001 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder
- Attention Deficit/Hyperactivity Disorder
- Nagata - Tsutae
- 2022-04-28
Recruiting
- Phase 3 Study of ALXN1850 versus Placebo in Adolescent and Adult Participants with HPP who have not previously been treated with Asfotase Alfa
- Hypophosphatasia
- Wuebbenhorst Hiroaki
- 2023-11-19